TB drug dosing under the microscope: could this lead to shorter, safer treatment?

NCT ID NCT02563327

Completed Knowledge-focused Sponsor: Centers for Disease Control and Prevention Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed Phase 3 study measured how high doses of the tuberculosis drugs rifapentine and moxifloxacin move through the body in 53 adults with TB. Participants gave multiple blood samples to track drug levels. The goal was to understand the best doses to kill TB bacteria while avoiding side effects. This research may help refine future TB treatment regimens.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine
What this could lead to: If successful, this study could help doctors choose the best doses of these TB drugs to cure patients faster and with fewer side effects.
What could go wrong: This is a small, intensive sampling study (53 participants) that looks at drug levels in the body, not a direct test of a new cure. Results may not apply to all TB patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG-SENSITIVE PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS

Contacts and locations

Locations

Joint Clinical Research Centre/ Makerere Univ Med Sch

Kampala, Uganda
National TB Program

Hanoi, Vietnam
University of Texas Health Science Center at

San Antonio, Texas, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.